Active Constituents of Magnolia officinalis in Cancer Management: Molecular Mechanisms and Therapeutic Potential
The American Journal of Chinese Medicine · 2026-01 · 54 (03) · 881-909
DOI: 10.1142/s0192415x26500321 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The American Journal of Chinese Medicine, online erschienen am 30.04.2026. Verfasst von Jiao Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Phytogenic, Drugs, Chinese Herbal, Magnolia, Neoplasms. Die Arbeit nennt 91 Literaturangaben. Gefördert von: Xing Lin Scholar Research Promotion Project of Chengdu University of Traditional Chinese Medicine.
Abstract (Originalsprache)
The global incidence and mortality of cancer continue to increase, and various chemotherapeutic agents, while highly effective, are associated with serious side effects like immunosuppression, metabolic dysfunction, and drug resistance. As a complementary or alternative approach, traditional Chinese medicine (TCM), which is known for its multi-target mechanisms and low toxicity, has garnered increasing attention in cancer research. Magnolia officinalis (M. officinalis) is a member of the Magnoliaceae family, and dried bark from its stems, roots, and branches is its primary medicinal part. According to TCM theory, M. officinalis may resolve dampness, eliminate phlegm, promote qi circulation, and relieve stagnation, and it has been widely applied in the treatment of gastrointestinal disorders. Modern pharmacological studies have identified bioactive compounds, including lignans, volatile oils, alkaloids, and polysaccharides, in M. officinalis, but the mechanisms underlying these pharmacological effects are still unclear and their clinical applications are limited by the lack of robust clinical evidence. We conducted a systematic review of both contemporary research databases (e.g., PubMed, CNKI, ScienceDirect, and other Chinese medical databases) and classic TCM literature to compile the bioactive components of M. officinalis, their pharmacological mechanisms in oncology, and recent preclinical progress. We also discuss the prospects and challenges of developing M. officinalis as an anticancer agent to provide a theoretical basis for its future development and clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- School of Public Health, Chengdu Medical College, Chengdu, China.
- Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing, China.
ORCID-Profile: Jiao Xia, Youqin Zeng, Yuting Ye, Changyou Wei, Ping Leng
Förderung
- Xing Lin Scholar Research Promotion Project of Chengdu University of Traditional Chinese Medicine
Zitieren
APA
Xia, J., Zeng, Y., Ye, Y., Wei, C., & Leng, P. (2026). Active Constituents of Magnolia officinalis in Cancer Management: Molecular Mechanisms and Therapeutic Potential. The American Journal of Chinese Medicine, 54(03), 881-909. https://doi.org/10.1142/s0192415x26500321
Vancouver
Xia J, Zeng Y, Ye Y, Wei C, Leng P. Active Constituents of Magnolia officinalis in Cancer Management: Molecular Mechanisms and Therapeutic Potential. The American Journal of Chinese Medicine. 2026;54(03):881-909. doi:10.1142/s0192415x26500321
BibTeX
@article{Xia2026,
author = {Xia, Jiao and Zeng, Youqin and Ye, Yuting and Wei, Changyou and Leng, Ping},
title = {Active Constituents of Magnolia officinalis in Cancer Management: Molecular Mechanisms and Therapeutic Potential},
journal = {The American Journal of Chinese Medicine},
year = {2026},
volume = {54},
number = {03},
pages = {881--909},
doi = {10.1142/s0192415x26500321}
}
EUVIMED